Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.
How it helps
Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.
With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.
How it works
Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.
Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.
Scrip
By Jessica Merrill 05 Dec 2018
The billionaire philanthropist and industry agitator took the stage at the Forbes Healthcare Summit to discuss why his foundation is focused on fixing drug pricing and supporting organizations like ICER and Patients for Affordable Drugs.
Scrip
By Mandy Jackson 05 Dec 2018
Late-breaker presentations at ASH showed that replacing chemotherapy agents with Imbruvica in CLL, and adding Darzalex to Revlimid and dexamethasone in multiple myeloma, is more effective than current standards of care in certain front-line settings.
Topic Cancer Drug approval
Scrip
By Jung Won Shin 05 Dec 2018
Application of artificial intelligence to new drug development in South Korea, which has been lagging in this area, is poised to accelerate as the country moves to support and encourage the technology.
Scrip
By Eleanor Malone 16 Nov 2018
Navigating the issues presented by biosimilars is becoming more complicated. With new barriers facing biosimilar originator companies and threatening to derail development, knowing how to formulate and manage your own biosimilar action plan is critically important.
Topic Biosimilars
Scrip
06 Nov 2018
November is Men’s Health Awareness Month, and Informa Pharma Intelligence is providing essential insights into drug developments for prostate cancer. Download now for free the "Men's Health: Drug Developments in Prostate Cancer Article Pack", brought to you by Scrip and Pink Sheet.
Scrip
By Kevin Grogan 31 Oct 2018
Two successful Phase III studies of Inlyta in combination with two distinct immunotherapies, including its own, Merck KGaA-partnered Bavencio, puts Pfizer in a very strong position in the advanced kidney cancer market.
Topic Cancer
Scrip
By Jessica Merrill 31 Oct 2018
Presiding over his last earnings call as the CEO of Pfizer, Ian Read was pressed about the company's drug pricing strategy for 2019 amid push back from the Trump Administration.
Topic Business strategies
Scrip
29 Oct 2018
Just how important is it to attend SCRIP Awards 2018? We’ve put together this short video to give you the facts and figures from last year’s awards – can you afford to miss this once-a-year opportunity?
Topic Clinical trials
Scrip
By Mike Ward 26 Oct 2018
A staple of consumer magazines and tabloid newspapers involves coverage of celebrity relationships – who has been seen together? Who is dating? Will they become a permanent item? And are they going to live happily ever after? Readers can’t seem to get enough of it. Interestingly, while maybe not so racy as the celebrity goings-on, pharma industry watchers are keen to follow company couplings. Talk of mergers and acquisitions, one of the ways that companies can build scale, always attracts attention.
Scrip
By Ian Haydock 26 Oct 2018
As part of broader efforts to pursue novel approaches to common neurological disorders, Eisai uses iPSC-derived cells to help identify potential new drug therapies for Parkinson's.
Topic Parkinsons disease
Scrip
26 Oct 2018
Clinicians and analysts have lauded spectacular results presented at ESMO from the SOLO-1 trial which strongly suggest that AstraZeneca's Lynparza should be the first-line maintenance treatment of choice for ovarian cancer patients with a BRCA mutation.
Topic Drug approval Cancer
Scrip
By Jessica Merrill 18 Oct 2018
PhRMA unveiled a voluntary policy under which drug makers will provide information in DTC ads about how to access drug prices and cost information. But hours later HHS issued a proposed rule on the same topic, only requiring drug makers to include WAC prices in TV ads.
Topic Drug approval Drug review
Scrip
By Alexandra Shimmings 18 Oct 2018
On the brink of an expanded US approval for asthma, Sanofi/Regeneron’s interleukin-4 receptor blocker Dupixent has produced positive topline Phase III data in a lucrative third indication, rhinosinusitis with nasal polyps.
Topic Influenza virus
Scrip
03 Oct 2018
The 2015 Scrip Lifetime Achievement Award was given to Sir Gregory Winter, Master of Trinity College, Cambridge (UK). Founder of Cambridge Antibody Technology (acquired by AstraZeneca), Domantis (acquired by GlaxoSmithKline) and Bicycle Therapeutics, he is best known for his pioneering research into humanizing antibodies. His findings led to the development of the first human antibody, Humira (adalimumab), until very recently the world's top-selling drug.
Scrip
By Jo Shorthouse 03 Oct 2018
Biochemist Greg Winter has scientifically contributed to some of the pharmaceutical industry's biggest commercial and therapeutic success stories. He tells Scrip how he feels about being labelled a pioneer and why he is still wary of the boardroom.
Topic Cancer
Scrip
07 Dec 2018
Scrip
07 Dec 2018
Scrip
07 Dec 2018
Scrip
07 Dec 2018
Scrip
07 Dec 2018
Scrip
07 Dec 2018
Scrip
07 Dec 2018
Scrip
07 Dec 2018
Scrip
06 Dec 2018
Scrip
06 Dec 2018
Scrip
06 Dec 2018
Scrip
06 Dec 2018
Scrip
06 Dec 2018
Scrip
06 Dec 2018
Scrip
06 Dec 2018
+31 year(s) experience
Denise specializes in
+27 year(s) experience
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
From discovery to patent expiry, and coverage spanning both ethical and generic drugs, Medtrack has you covered. Stay current on key financing, drug and biologics development and drug manufacturing information, all with a single tool.
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Looking for more products Product Finder
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Keep up to date